Distribution of total net revenues

MSEK

2017

Jan-Mar

2016

Jan-Mar

2016

Jan-Dec

Zubsolv® US

114.1

98.4

481.8

Zubsolv – Rest of the World

-

-

65.9

Zubsolv – total               

114.1

98.4

547.7

Abstral® royalties

8.7

8.2

100.4

Milestone payment Abstral

-

-

2.2

Abstral – total

8.7

8.2

102.6

Edluar® royalties

4.6

3.6

14.8

Other revenues1

-

40.8

40.8

Total

127.4

151.0

705.9

 1Relates to the acquisition of OC-CLI by AstraZeneca 

 Key figures

 

2017
Jan-Mar

2016
Jan-Mar

2016
Jan-Dec

EBIT margin, %

-18

-17

7

Return on shareholder equity, %

-12

-14

10

Net debt, MSEK

88.8

261.9

115.4

Debt/equity ratio, %

124.2

208.6

128.2

Equity/assets ratio, %

29.2

23.1

30.5

Number of shares, before dilution

34,539,585

34,447,779

34,477,375

Number of shares, after dilution

34,539,585

34,447,779

34,574,337

Earnings per share, before dilution, SEK

-1.00

-1.00

0.84

Earnings per share, after dilution, SEK

-1.00

-1.00

0.84

Number of employees at the end of the period

102

93

102

Shareholders’ equity, MSEK

273.3

237.3

310.3

Capital employed, MSEK

612.7

732.2

708.1

Working capital, MSEK

436.9

552.6

524.2

 Cash flow

 

MSEK

2017

Jan-Mar

2016

Jan-Mar

2016

Jan-Dec

Cash flow from operating activities

28.2

33.5

156.2

Investment activities

-0.3

-0.1

5.4

Financing activities

-59.0

0.0

-90.6

Cash flow (excl exchange rate differences)

-31.1

33.4

71.0

Liquid funds

250.6

233.0

282.4